NeuCyte, winner of the NIH Common Fund’s Complement-ARIE Challenge prize
Mountain View, CA, USA, May 14, 2024 - NeuCyte, Inc. is an innovative biotechnology company focused on developing novel treatments for neurological and neurodegenerative disorders. NeuCyte is working with Dr. Riccardo Barrile who was recently awarded a NIH Common Fund Complement Animal Research In Experimentation (Complement-ARIE), a crowdsourcing competition for innovative ideas on New Approach Methodologies, or NAMs. The Complement-ARIE Challenge prize competition offered $1,000,000 in total prize money to diverse teams with ideas for new ways of using NAMs to conduct basic research, uncover disease mechanisms, and translate knowledge into products and practice.
NeuCyte will be a member of the NeuroTech Innovations Team, along with team captain Dr. Riccardo Barrile and Dr. Ryan White of the University of Cincinnati. Using cells from patients with Alzheimer Disease (AD), the NeuroTech Innovations Team will assemble microphysiological systems to model the impact of AD on the blood brain barrier, capturing the complex structural and functional cellular interactions that form the disease-relevant neurovascular unit. By incorporating real-time bio-sensors into these models, the efforts of this award will provide a key tool for understanding the mechanisms that regulate the nervous system in healthy and disease states and offer a novel platform for identification of therapeutic strategies.
​
About NeuCyte, Inc
NeuCyte is an innovative biotech company focused on generating quality induced pluripotent stem (iPSC)-derived neural cells to aid drug discovery efforts. Based on proprietary SynFire® technology for generating human iPSC-derived neural cells, NeuCyte has developed highly functional in vitro platforms that allow us to focus our work on 3D organoid Microphysiological systems (MPS), enabling disease modeling, neurotoxicity testing, phenotypic drug discovery, target identification, and compound efficacy studies. Our robust platform allows us to differentiate iPSCs from any background into a range of neural cell types, including neurons, astrocytes, and microglia to find treatments and solutions for AD, ALS/FTD, rare disorders, epilepsy, autism, and other neurodegenerative diseases.
​
For more information, visit www.neucyte.com.
​
About NIH Complement-ARIE program
The NIH Common Fund’s Complement Animal Research In Experimentation (Complement-ARIE), is a program designed to accelerate the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs). Building upon ongoing efforts related to NAMs, the Complement-ARIE program is focused on identifying opportunities for innovation and coordination. The Complement-ARIE program aims to significantly advance our understanding of human health and disease by providing a range of ready and standardized biomedical research models. Key components of Complement-ARIE include technology development projects, a data & NAM resource coordinating center, a validation network, community engagement, and strategic partnerships, the efforts of which will significantly advance our understanding of human health and disease.
​
For more information, visit www.commonfund.nih.gov/complementarie.
​
​
​
Contact information:
Wayne Poon, PhD
NeuCyte, Inc
319 N Bernardo Avenue
Mountain View, CA